

1 **Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources.**

2

3 Daniele Focosi<sup>1, #</sup>, Massimo Franchini<sup>2</sup>, Michael J. Joyner<sup>3</sup>, Arturo Casadevall<sup>4</sup>, David J Sullivan<sup>4</sup>

4

5 <sup>1</sup>North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.

6

7 <sup>2</sup>Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy; [massimo.franchini@asst-](mailto:massimo.franchini@asst-mantova.it)  
8 [mantova.it](http://mantova.it)

9 <sup>3</sup>Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA  
10 [joyner.michael@mayo.edu](mailto:joyner.michael@mayo.edu) ;

11 <sup>4</sup>Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, MD  
12 21218, USA; [acasade1@jhu.edu](mailto:acasade1@jhu.edu)<sup>#</sup> corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail:  
13 [daniele.focosi@gmail.com](mailto:daniele.focosi@gmail.com) .

14 **Keywords:** COVID19; Omicron; convalescent plasma; vaccine; neutralizing antibodies.

15 **Word count:** abstract 210; body 2979.

16 **Acknowledgements:** none.

17 **Funding Information:** The analysis was supported by the U.S. Department of Defense's Joint Program  
18 Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in  
19 collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (D.S), with  
20 additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health  
21 (NIH) National Institute of Allergy and Infectious Diseases (NIAID) 3R01AI152078-01S1) (A.C).

22 **Author contributions:** D.F. and M.J.J. conceived the manuscript; D.F., D.J.S. and M.F. analyzed the  
23 literature, curated tables and wrote manuscripts; M.F. provided Figure 1; D.J.S. provided Figures 2 -4.A.C.  
24 and M.J.J. revised the manuscript.

25 **Data availability statement:** The datasets generated during and/or analysed during the current study are  
26 available from the corresponding author on reasonable request

27

## 28 Abstract

29 The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike  
30 monoclonal antibodies and vaccine-elicited sera, demonstrates the continued relevance of COVID19  
31 convalescent plasma (CCP) therapies. Lessons learnt from previous usage of CCP suggests focusing on  
32 outpatients and immunocompromised recipients, with high neutralizing antibody (nAb) titer units. In this  
33 analysis we systematically reviewed Omicron neutralizing plasma activity data, and found that  
34 approximately 50% (426/911) of CCP from unvaccinated donors neutralizes Omicron with a very low  
35 geometric mean of geometric mean titers for 50% neutralization ( $GM(GMT_{50})$ ) of about 17, representing  
36 a more than 24-fold reduction from paired WA-1 neutralization. Two doses of mRNA vaccines in  
37 nonconvalescent subjects had a similar 50% percent neutralization with Omicron neutralization  
38  $GM(GMT_{50})$  about 24. However, CCP from vaccinees recovered from previous variants of concern or  
39 third-dose uninfected vaccinees was nearly 100% neutralizing with Omicron  $GM(GMT_{50})$  over 200, a 12-  
40 fold Omicron neutralizing antibody increase compared to unvaccinated convalescents from former VOCs.  
41 These findings have implications for both CCP stocks collected in prior pandemic periods and plans to  
42 restart CCP collections. Thus, CCP from vaccinated donors provides an effective tool to combat variants  
43 that defeat therapeutic monoclonal antibodies.

## 44 Introduction

45 The SARS-CoV-2 Omicron variant of concern (VOC) (originally named VUI-21NOV-01 by Public Health  
46 England and belonging to GISAID clade GRA(B.1.1.529+BA.\*) was first reported on November 8, 2021 in  
47 South Africa, and shortly thereafter was also detected all around the world. Omicron mutations impact  
48 27% of T cell epitopes<sup>1</sup> and 31% of B cell epitopes of Spike, while percentages for other VOC were much  
49 lower<sup>2</sup>. The Omicron variant has further evolved to several sublineages which are named by PANGO  
50 phylogeny using the BA alias: the BA.1 wave of Winter 2021-2022 has been suddenly replaced by BA.2  
51 and BA.2.12.1 in Spring 2022, and by the BA.4 and BA.5 waves in Summer 2022..

52  
53 The VOC Omicron is reducing the efficacy of all vaccines approved to date (unless 3 doses are delivered)  
54 and is initiating an unexpected boost in COVID19 convalescent plasma (CCP) usage, with Omicron being  
55 treated as a shifted novel virus instead of a SARS-CoV-2 variant drift. Two years into the pandemics, we  
56 are back to the starting line for some therapeutic classes. Specifically, Omicron escapes viral  
57 neutralization by most monoclonal antibodies (mAbs) authorized to date with the lone exception of  
58 bebtelovimab<sup>3</sup>. Despite the development of promising oral small-chemical antivirals (molnupiravir and  
59 nirmatrelvir), the logistical and economical hurdles for deploying these drugs worldwide has prevented  
60 their immediate and widespread availability, and concerns remain regarding both molnupiravir (both  
61 safety<sup>4</sup> and efficacy<sup>5</sup>) and nirmatrelvir (efficacy), especially in immunocompromised subjects. COVID19  
62 convalescent plasma (CCP) was used as a frontline treatment from the very beginning of the pandemic.  
63 Efficacy outcomes have been mixed to date, with most failures explained by low dose, late usage, or  
64 both, but efficacy of high-titer CCP has been definitively proven in outpatients with mild disease stages<sup>6</sup>.  
65 Neutralizing antibody (nAb) efficacy against VOC remains a prerequisite to support CCP usage, which  
66 can now be collected from vaccinated convalescents, including donors recovered from breakthrough  
67 infections (so-called “hybrid” or “VaxCCP”)<sup>8</sup>: pre-Omicron evidence suggest that those nAbs have higher  
68 titers and are more effective against VOCs than those from unvaccinated convalescents<sup>9, 10</sup>. From a  
69 regulatory viewpoint, to date, plasma from vaccinees that have never been convalescent does not fall  
70 within the FDA emergency use authorization

71 There are tens of different vaccine schedules theoretically possible according to EMA and FDA approvals,  
72 including a number of homologous or heterologous boosts, but the most commonly delivered schedules  
73 in the western hemisphere have been: 1) BNT162b2 or mRNA-1273 for 2 doses eventually followed by a  
74 homologous boost; 2) ChAdOx1 for 2 doses eventually followed by a BNT162b2 boost; and 3)  
75 Ad26.COV2.S for 1 dose eventually followed by a BNT162b2 boost<sup>11</sup>. Many more inactivated vaccines  
76 have been in use in low-and-middle income countries (LMIC), which are target regions for CCP therapy:  
77 this is feasible given the lower number of patients at risk for disease progression there (lower incidences  
78 of obesity, diabetes, and hypertension, and lower median age) and the already widespread occurrence of  
79 collection and transfusion facilities. Most blood donors there have already received the vaccine schedule  
80 before, after or without having been infected, with a nAb titer generally declining over months<sup>12</sup>. Hence  
81 identifying the settings where the nAb titer is highest will definitively increase the efficacy of CCP  
82 collections. Variations in nAb titers against a given SARS-CoV-2 strain are usually reported as fold-changes  
83 in geometric mean titer of antibodies neutralizing 50% of cytopathic effect or foci (GMT<sub>50</sub>) compared to  
84 wild-type strains: nevertheless, fold-changes for groups that include non-responders can lead to highly  
85 artificial results and possibly over-interpretation. Rigorous studies have hence reported the percentage of

86 responders as primary outcome and provided fold-changes of GMT<sub>50</sub> where calculation is reasonable  
87 (100% responders in both arms)<sup>13</sup>.

88 To date the most rigorous data repository for SARS-CoV-2 sensitivity to antivirals is the Stanford  
89 University Coronavirus Antiviral & Resistance Database, but as of July 24, 2022 the tables there  
90 summarizing “Convalescent plasma” and “Vaccinee plasma” ([https://covdb.stanford.edu/search-](https://covdb.stanford.edu/search-drdb/?form_only)  
91 [drdb/?form\\_only](https://covdb.stanford.edu/search-drdb/?form_only) ) do not dissect the different heterologous or homologous vaccination schemes, the  
92 simultaneous occurrence of vaccination and convalescence, or the time from infection/vaccine to  
93 neutralization assay. Consequently, a more in-depth analysis is needed to better stratify CCP types.

94

## 95 Methods

96 On August 11, 2022, we searched PubMed, medRxiv and bioRxiv for research investigating the efficacy of  
97 CCP (either from vaccinated or unvaccinated donors) against SARS-CoV-2 VOC Omicron for article  
98 (pre)published after December 1, 2019, using English language as the only restriction. In PubMed we  
99 used the search query (“convalescent plasma” or “convalescent serum”) AND (“neutralization” or  
100 “neutralizing”) AND “SARS-CoV-2”, while in bioRxiv and medRxiv we searched for abstract or title  
101 containing “convalescent, SARS-CoV-2, neutralization” (match all words). When a preprint was published,  
102 the latter was used for analysis. We also screened the reference lists of reviewed articles for additional  
103 studies not captured in our initial literature search. Articles underwent evaluation for inclusion by two  
104 assessors (D.F. and D.S.) and disagreements were resolved by a third senior assessor (A.C.). We excluded  
105 review articles, meta-analyses, studies reporting antibody levels by serological assays other than  
106 neutralization, as well as studies exclusively analyzing nAbs in vaccine-elicited plasma/serum from non-  
107 convalescent subjects. In unvaccinated subjects, convalescence was annotated according to infecting  
108 sublineage (pre-VOC Alpha, VOC Alpha, VOC Beta, VOC Delta, or VOC Omicron sublineages). Given the  
109 heterologous immunity that develops after vaccination in convalescents, the infecting lineage was not  
110 annotated in vaccine recipients. In vaccinees, strata were created for 2 homologous doses, 3 homologous  
111 doses, or post-COVID-19 and post-vaccination (Vax-CCP). The mean neutralizing titer for WA-1 (pre-Alpha  
112 wild-type), Omicron and number out of total that neutralized Omicron was abstracted from studies.

113 Statistical significance between means was investigated using Tukey’s test.

114

## 115 Results

116 Our literature search identified 29 studies dealing with the original Omicron lineage (BA.1), that were  
117 then manually mined for relevant details : the PRISMA flowchart for study selection is provided in Figure  
118 1. Given the urgency to assess efficacy against the upcoming VOC Omicron, most studies (with a few  
119 exceptions<sup>14, 15, 16, 17</sup>) relied on Omicron pseudovirus neutralization assays, which, as opposed to live  
120 authentic virus, are scalable, do not require BSL-3 facilities, and provide results in less than 1 week.  
121 GMT<sub>50</sub> of nAb and fold-reduction (in GMT<sub>50</sub> against Omicron compared to wild-type SARS-CoV-2 (e.g.,  
122 WA-1) were the most common ways of reporting changes, which reduces variability due to difference in  
123 neutralization assays used.

124 Figure 2 and Table 1 summarize that neutralizing activity to WA-1 from CCP collected from subjects  
125 infected with pre-Alpha SARS-CoV-2 (Supplementary Table 1), Alpha VOC (Supplementary Table 2), Beta  
126 VOC (Supplementary Table 3), Delta VOC (Supplementary Table 4) or plasma from nonconvalescent  
127 subjects vaccinated with 2 mRNA vaccine doses (Supplementary Tables 5 and 6) The same plasma types  
128 computed a geometric mean of multiple GMT<sub>50</sub> from many studies with about a 21-fold reduction against  
129 BA.1 geomeans compared to wild-type SARS-CoV-2 geomeans. CCP from uninfected vaccinees receiving a  
130 third vaccine dose registered geomean of the GMT<sub>(50)</sub> of 2,723 (or 10- fold higher nAb geomean of the  
131 GMT<sub>50</sub>) to wild-type viral assays: in this group the nAb geomean of the GMT<sub>50</sub> fold-reduction against BA.1  
132 was 9, but importantly the geomean of the GMT<sub>(50)</sub> was close to 291 again. The approximately 21-fold  
133 reduction in nAb geomean of the GMT<sub>(50)</sub> from wild-type to BA.1 was reversed by the 10-15-fold  
134 increase in nAb geomean of the GMT<sub>(50)</sub> from either boosted vaccination or VaxCCP.

135 In addition to the nAb GMT<sub>50</sub> levels showing potency, the percentage of individuals within a study cohort  
136 positive for any level of BA.1 neutralization shows the likelihood of a possible donation having anti-BA.1  
137 activity. All studies but one tested a limited number of 20 to 40 individuals. The pre-Alpha CCP showed  
138 that most (18 of 27 studies) had less than 50% of individuals tested within a study with measurable BA.1  
139 neutralizing activity: only 2 out of 27 studies indicated 100% of individuals tested showed BA.1  
140 neutralization (Figure 3). Likewise, most of the studies investigating Alpha and Beta CCP showed similar  
141 percent with nAb. Delta CCP had 6 of 7 studies with more than 50% BA.1 neutralization. The plasma from  
142 studies of the 2-dose mRNA vaccines indicated a more uniform distributive increase in percent of  
143 individual patients with measurable Omicron nAb's. The stark contrast is Vax-CCP, where 16 of 19 studies  
144 had 100% of individuals tested with anti-BA.1 nAb. The 3-dose vaccinee studies similarly had 12 of 17  
145 studies with 100% measurable nAb.

146 There were 5 studies which directly compared anti-WA-1 versus BA.1 nAb titers in nonvaccinated pre-  
147 Alpha, Alpha, Beta, and Delta CCP, and vaccinated plasma with the same nAb assay (Figure 4). nAb GMT<sub>50</sub>  
148 against WA-1 was higher for Alpha and Delta CCP but lower for Beta CCP. nAb geomean of the GMT<sub>(50)</sub>  
149 against BA.1 was actually highest for Beta CCP 13 geomean with geomean levels of 9, 8, 10 for pre-Alpha,  
150 Alpha and Delta (Figure 4, panel A). In these 5 studies, nAb geomean of the GMT<sub>(50)</sub> rose from 2-dose  
151 vaccinations to VaxCCP to the 3-dose boosted vaccination. Importantly, for nAb geomean of the GMT<sub>(50)</sub>  
152 against BA.1 were 13 to 103 to 223, respectively representing a 8 to 17-fold rise (Figure 4, panel B).

153 Another set of 9 matched vaccination studies inclusive of plasma collected after 2- and 3-dose schedules,  
154 as well as Vax-CCP depicted a 23-fold rise in geomean of the GMT<sub>(50)</sub> of anti-BA.1 nAb from the 2-dose  
155 vaccine to post COVID-19 vaccinees, and a 21-fold increase after the third vaccine dose. The pattern was  
156 similar for nAb geomean of the GMT<sub>(50)</sub> against WA-1 (Figure 4, panel C).

157 The AZD1222, 3-dose mRNA-1273 and Ad26.CO2 vaccines were understudied, with 3 or less  
158 independent studies at different time points, reported in Table 10. The GMT<sub>50</sub> nAb to BA.1 after 3-  
159 mRNA-1273 doses ranged 60 to 2000, with a 5 to 15 fold reduction compared with WA-1. GMT<sub>50</sub> of anti-  
160 BA.1 nAbs after AZD1222 vaccine was modest (~10 to 20), as with Ad26.CO2 vaccine (~20 to 40). Two  
161 studies reported on post-COVID-19/post-mRNA-1273 with nAb GMT<sub>50</sub> against BA.1 of 38 and 272. Studies  
162 with 100% of individual patient samples neutralizing BA.1 included 2 3-dose mRNA-1273 studies, one  
163 AZD1222 study, and one post-COVID-19/post-mRNA-1273 study.

164 Few data exist for comparisons among different vaccine boosts. For CoronaVac® (SinoVac), three doses  
165 led to 5.1 fold reduction in anti-BA.1 nAb GMT<sub>50</sub> compared to wild-type<sup>18</sup>, while for Sputnik V nAb titer  
166 moved from a 12-fold reduction at 6-12 months up to a 7-fold reduction at 2-3 months after a boost with  
167 Sputnik Light<sup>19, 20</sup>. These *in vitro* findings have been largely confirmed *in vivo*, where prior heterologous  
168 SARS-CoV-2 infection, with and without mRNA vaccination, protects against BA.1 re-infection<sup>21</sup>.

169

170 Twenty-one studies analyzed the efficacy of CCP and VaxCCP against Omicron sublineages other than  
171 BA.1 (summarized in Table 2). Those studies largely confirmed that Omicron CCP *per se* is poorly effective  
172 against the cognate or other Omicron sublineages<sup>22</sup> (with the lone exception of cross-reactions among  
173 lineages sharing L452 mutations<sup>23</sup> and broad-spectrum nAbs elicited by BA.5<sup>24</sup>). On the contrary, both  
174 homologous and heterologous efficacy of Omicron VaxCCP is again universally preserved<sup>15, 25</sup>. Despite  
175 evidences that concentrated pooled human IgG from convalescent and vaccinated donors has 5-fold  
176 reduced potency against BA.5 compared to wild-type SARS-CoV-2<sup>26</sup>, such VaxCCP derivative is devoid of  
177 IgA and IgM nAbs. These findings have important implications if a VaxCCP program is going to be re-  
178 launched at the time of BA.2 and BA.4/5 waves. In particular, the emerging R346X-harboring BA.4.6,  
179 BA.4.7, and BA.5.9 sublineages show 1.5-1.9-fold reduction in GMT<sub>50</sub> by BA.1/2 VaxCCP and 2.4-2.6  
180 reduction by BA.5 VaxCCP<sup>27</sup>. Of interest, VaxCCP after 2 doses remains superior to 4-dose vaccinee  
181 plasma, and VaxCCP with 3 vaccine doses is not consistently superior to VaxCCP after 2 vaccine doses<sup>28</sup>.

182

## 183 Discussion

184 Since nAbs are by definition antiviral, CCP with a high nAb GMT<sub>50</sub> is preferable, and there is now strong  
185 clinical evidence that nAb titers correlate with clinical benefit in randomized clinical trials<sup>6, 7</sup>. Although  
186 nAb titers correlate with vaccine efficacy<sup>29, 30</sup>, it is important to keep in mind that SARS-CoV-2-binding  
187 non-neutralizing antibodies can similarly provide protection via Fc-mediated functions<sup>31, 32</sup>. However,  
188 such functions are harder to measure and no automated assay exist for use in clinical laboratories.  
189 Hence, whereas the presence of a high nAb GMT<sub>50</sub> in CCP is evidence for antibody effectiveness *in vitro*,  
190 the absence of nAb titer does not imply lack of protection *in vivo* where Fc effects mediate protection by  
191 other mechanisms such as antibody-dependent cell-mediated cytotoxicity, complement activation and  
192 phagocytosis.

193 The mechanism by which CCP from vaccinated COVID-19 convalescent individuals better neutralizes  
194 Omicron lineages probably a combination of higher amounts of nAb and broader antibody specificity.  
195 Higher amounts of antibody could neutralize antigenically different variants through the law of mass  
196 action<sup>33</sup> whereby even lower affinity antibodies elicited to earlier variants would bind to the Omicron  
197 variant as mass compensates for reduced binding strength to drive the reaction forward. In addition,  
198 vaccinated COVID-19 convalescent individuals would have experienced SARS-CoV-2 protein in two  
199 antigenically different forms: as part of intact infective virions generated *in vivo* during an infectious  
200 process and as antigens in vaccine preparations. As the immune system processes the same antigen in  
201 different forms, there are numerous opportunities for processing the protein in different manners that  
202 can diversity the specificity of the immune response and thus increase the likelihood of eliciting

203 antibodies that react with variant proteins. Structurally, it has been shown that third dose mRNA  
204 vaccination induces mostly class 1/2 antibodies encoded by IGHV1-58;IGHJ3-1 and IGHV1-69;IGHJ4-1  
205 germlines, but not the IGHV2-5;IGHJ3-1 germline, broadly cross-reactive Class 3 antibodies seen after  
206 infection<sup>34</sup>.

207 Our analysis provides strong evidence that, unlike what has been observed in Syrian hamster models<sup>35</sup>,  
208 CCP from unvaccinated donors is unlikely (less than 50%) to have any measurable Omicron neutralization.  
209 Although the nAb GMT<sub>50</sub> threshold for clinical utility remains poorly defined, it is noticeable that low BA.1  
210 nAb GMT<sub>50</sub> were generally detected in CCP after infection from pre-Omicron VOCs.

211 On the contrary, despite the huge heterogeneity of vaccine schedules, CCP from vaccinated and COVID-  
212 19 convalescent individuals (Vax-CCP) consistently harbors high nAb titers against BA.1 and novel  
213 sublineages if collected up to 6 months since last event (either vaccine dose or infection). These Omicron  
214 neutralizing levels are comparable in dilutional titers to that of WA-1 CCP neutralizing WA-1, but their  
215 prevalence is much higher at this time, facilitating recruitment of suitable donors. Pre-Omicron CCP  
216 boosted with WA-1-type vaccines induces heterologous immunity that effectively neutralizes Omicron in  
217 the same assays which rule in or out therapeutic anti-Spike monoclonal antibodies. Consequently,  
218 prescreening of Vax-CCP donors for nAb titers is not necessary, and qualification of Vax-CCP units remains  
219 advisable only within clinical trials. A more objective way to assess previous infection (convalescence)  
220 would be measuring anti-nucleocapsid (N) antibodies, but unfortunately these vanish quickly<sup>36, 37</sup>.  
221 Previous symptomatic infection and vaccination can be established by collecting past medical history  
222 (PMH) during the donor selection visit, which is cheaper, faster, and more reliable than measuring rapidly  
223 declining anti-N antibodies. Although there is no formal evidence for this, it is likely that asymptomatic  
224 infection (leading to lower nAb levels in pre-Omicron studies) also leads to lower nAb levels after  
225 vaccination compared to symptomatic infection, given that disease severity correlates with antibody titer  
226<sup>38, 39</sup>; hence those asymptotically infected donors missed by investigating PMH are also less likely to be  
227 useful.

228 The same reasoning applies to uninfected vaccinees receiving third dose boosts, but several authorities,  
229 including the FDA, do not currently allow collection from such donors for CCP therapy on the basis that  
230 the convalescent polyclonal and poly-target response is a prerequisite for efficacy and superior to the  
231 polyclonal anti-Spike-only response induced by vaccinees. This may be a false premise for recipients of  
232 inactivated whole-virus vaccines (e.g., BBIBP-CorV or VLA2001): for BBIBP-CorV, the efficacy against  
233 Omicron is largely reduced<sup>18, 20, 40</sup>, but the impact of boost doses is still unreported at the time of writing.  
234 Table 1 and Table 9 clearly show that 3-doses of BNT162b2 are enough to restore nAb levels against  
235 Omicron in the absence of SARS-CoV-2 infection.

236 Another point to consider is that information on nAb levels after the third vaccine dose has been almost  
237 exclusively investigated for only 1 month of follow-up, while studies on convalescents extend to more  
238 than 6 months: to date it seems hence advisable to start from convalescent vaccinees rather than  
239 uninfected 3-dose vaccinees. This is also confirmed by immune escape reported *in vivo* after usage of  
240 vaccine (non-convalescent) plasma<sup>41</sup> despite very high nAb titres, likely due to restricted antigen  
241 specificity. Vaccine schedules with a delayed boost seem to elicit higher and broader nAb levels than the  
242 approved, short schedules<sup>42, 43, 44, 45</sup>, but this remain to be confirmed in larger series. The same is true for

243 breakthrough infections from Alpha or Delta VOC in fully BNT162b2 vaccinated subjects<sup>46</sup>, although  
244 variation in time from infection due to successive waves is a major confounder.

245 With the increase of Omicron seroprevalence in time, polyclonal intravenous immunoglobulins collected  
246 from regular donors could become a more standardized alternative to CCP, but their efficacy to date (at  
247 the peak of the vaccinations campaign) is still 16-fold reduced against Omicron compared to wild-type  
248 SARS-CoV-2<sup>47</sup>, and such preparations include only IgG and not IgM and IgA, which have powerful SARS-  
249 CoV-2 activity<sup>48, 49</sup>. Nevertheless, FDA recently reported efficacy of hyperimmune serum against BA.1,  
250 BA.2, BA.3, BA.2.12.1, and BA.4/5<sup>50</sup>.

251 CCP collection from vaccinated convalescents (regardless of infecting sublineage, vaccine type and  
252 number of doses) is likely to achieve high nAb titer against VOC Omicron, and, on the basis of lessons  
253 learnt with CCP usage during the first 2 years of the pandemic. Although in ideal situations one would  
254 prefer RCT evidence of efficacy against Omicron before deployment, there is concern that variants are  
255 generated so rapidly that by the time such trials commenced this variant could be replaced for another.  
256 Given the success of CCP in 2 outpatient RCTs reducing hospitalization<sup>6, 7</sup> and the loss of major mAb  
257 therapies due to Omicron antigenic changes, the high titers in CCP collected from vaccinated  
258 convalescents provides an immediate option for COVID-19, especially in LMIC. Given the reduced  
259 hospitalization rate with Omicron compared to Delta<sup>51</sup>, it is even more relevant to identify patient  
260 subsets at risk of progression in order to minimize the number needed to treat to prevent a single  
261 hospitalization: moving from the same criteria used for mAb therapies while using the same (now  
262 unused) in-hospital facilities seems a logical approach.

263 We declare we have no conflict of interest related to this manuscript.

264

## 265 References

- 266 1. Ahmed SF, Quadeer AA, McKay M. SARS-CoV-2 T cell responses are expected to remain  
267 robust against Omicron. *Viruses* **14**, 79 (2022).
- 268 2. Bernasconi A, *et al.* Report on Omicron Spike mutations on epitopes and  
269 immunological/epidemiological/kinetics effects from literature. Accessed at  
270 [https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770)  
271 [immunological-epidemiological-kinetics-effects-from-literature/770](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770) on July 23, 2022.)  
272 (2021).  
273
- 274 3. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal  
275 antibody therapies against SARS-CoV-2. *Lancet Infect Dis*, (2022).  
276
- 277 4. Zhou S, *et al.*  $\beta$ -d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is  
278 Also Mutagenic To Mammalian Cells. *The Journal of Infectious Diseases* **224**, 415-419 (2021).  
279

280



- 281 5. Jayk Bernal A, *et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.  
282 *N Engl J Med* **386**, 509-520 (2022).
- 283
- 284 6. Libster R, *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.  
285 *N Engl J Med* **384**, 610-618 (2021).
- 286
- 287 7. Sullivan D, *et al.* Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl J*  
288 *Med*, (2021).
- 289
- 290 8. Vickers MA, *et al.* Exponential increase in neutralizing and spike specific antibodies following  
291 vaccination of COVID-19 convalescent plasma donors. *Transfusion* **61**, 2099-2106 (2021).
- 292
- 293 9. Schmidt F, *et al.* High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.  
294 *Nature* **600**, 512-516 (2021).
- 295
- 296 10. Di Germanio C, *et al.* Vaccination of COVID-19 Convalescent Plasma Donors Increases  
297 Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants. *Transfusion* **62**, 563-569  
298 (2021).
- 299
- 300 11. Munro APS, *et al.* Safety and immunogenicity of seven COVID-19 vaccines as a third dose  
301 (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a  
302 blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet* **398**, 2258-2276  
303 (2021).
- 304
- 305 12. Franchini M, *et al.* Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta  
306 and Omicron in vaccine breakthrough-infected blood donors. *Transfusion* **62**, 1171-1176  
307 (2022).
- 308
- 309 13. Jacobsen H, *et al.* Diminished neutralization responses towards SARS-CoV-2 Omicron VoC  
310 after mRNA or vector-based COVID-19 vaccinations. 2021.2012.2021.21267898 (2021).
- 311
- 312 14. Planas D, *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.  
313 *Nature* **602**, 671-675 (2022).
- 314
- 315 15. Bekliz M, *et al.* Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma,  
316 Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through  
317 homologous and heterologous variants. 2021.2012.2028.21268491 (2021).
- 318
- 319 16. Rossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant  
320 Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med* **386**, 698-  
321 700 (2022).

- 322  
323 17. Muik A, *et al.* Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited  
324 human sera. *Science (New York, NY)* **375**, 678-680 (2022).
- 325  
326 18. Zhao X, *et al.* Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and  
327 protein subunit vaccines and the convalescents. 2021.2012.2016.472391 (2021).
- 328  
329 19. Dolzhikova IV, *et al.* Sputnik Light booster after Sputnik V vaccination induces robust  
330 neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant.  
331 2021.2012.2017.21267976 (2021).
- 332  
333 20. Bowen JE, *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive  
334 panel of human vaccines. 2022.2003.2015.484542 (2022).
- 335  
336 21. Carazo S, *et al.* Protection against Omicron re-infection conferred by prior heterologous  
337 SARS-CoV-2 infection, with and without mRNA vaccination. 2022.2004.2029.22274455  
338 (2022).
- 339  
340 22. Turelli P, *et al.* Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing  
341 activity. 2022.2005.2002.22274436 (2022).
- 342  
343 23. Qu P, *et al.* Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. *N*  
344 *Engl J Med* **386**, 2526-2528 (2022).
- 345  
346 24. Richardson SI, *et al.* SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing  
347 antibodies than BA.1. 2022.2007.2014.500039 (2022).
- 348  
349 25. Zhou R, *et al.* Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits  
350 broadly cross-reactive immune responses. *Clin Transl Med* **2**, e720 (2022).
- 351  
352 26. Aggarwal A, *et al.* SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent  
353 humoral responses and resistance to clinical immunotherapeutics relative to viral variants of  
354 concern. 2022.2007.2007.22277128 (2022).
- 355  
356 27. Jian F, *et al.* Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5  
357 subvariants. 2022.2008.2009.503384 (2022).
- 358  
359 28. Xie X, Zou J, Kurhade C, Liu M, Ren P, Shi P-Y. Neutralization of SARS-CoV-2 Omicron  
360 sublineages by 4 doses of mRNA vaccine. 2022.2007.2029.502055 (2022).
- 361

- 362 29. Khoury DS, *et al.* Neutralizing antibody levels are highly predictive of immune protection  
363 from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
- 364
- 365 30. Feng S, *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2  
366 infection. *Nat Med* **27**, 2032-2040 (2021).
- 367
- 368 31. Gilbert PB, *et al.* Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy  
369 clinical trial. *Science*, eab3435 (2021).
- 370
- 371 32. Earle KA, *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines.  
372 *Vaccine* **39**, 4423-4428 (2021).
- 373
- 374 33. Tyrrell DA. Neutralization of viruses by homologous immune serum. II. Theoretical study of  
375 the equilibrium state. *The Journal of experimental medicine* **97**, 863-870 (1953).
- 376
- 377 34. Andreano E, *et al.* COVID-19 mRNA third dose induces a unique hybrid immunity-like  
378 antibody response. 2022.2005.2009.491201 (2022).
- 379
- 380 35. Ryan KA, *et al.* Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from  
381 disease caused by the Omicron variant. 2021.2012.2024.474081 (2021).
- 382
- 383 36. Krutikov M, *et al.* Prevalence and duration of detectable SARS-CoV-2 nucleocapsid  
384 antibodies in staff and residents of long-term care facilities over the first year of the  
385 pandemic (VIVALDI study): prospective cohort study in England. *The Lancet Healthy  
386 Longevity*, (2021).
- 387
- 388 37. Amjadi MF, *et al.* Anti-membrane and anti-spike antibodies are long-lasting and together  
389 discriminate between past COVID-19 infection and vaccination. 2021.2011.2002.21265750  
390 (2021).
- 391
- 392 38. Klein S, *et al.* Sex, age, and hospitalization drive antibody responses in a COVID-19  
393 convalescent plasma donor population. *The Journal of clinical investigation* **130**, 6141-6150  
394 (2020).
- 395
- 396 39. Focosi D, Franchini M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in  
397 COVID-19 convalescents: Implications for convalescent plasma donor recruitment. *European  
398 journal of haematology* **107**, 24-28 (2021).
- 399
- 400 40. Yu X, *et al.* Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from  
401 neutralization induced by a third booster dose of vaccination. 2021.2012.2017.21267961  
402 (2021).

- 403  
404 41. Gachoud D, *et al.* Antibody response and intra-host viral evolution after plasma therapy in  
405 COVID-19 patients pre-exposed or not to B-cell depleting agents. 2022.2004.2024.22274200  
406 (2022).
- 407  
408 42. Chatterjee D, *et al.* SARS-CoV-2 Omicron Spike recognition by plasma from individuals  
409 receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. *Cell Rep* **38**,  
410 110429 (2022).
- 411  
412 43. Grunau B, *et al.* Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.  
413 *JAMA* **327**, 279-281 (2022).
- 414  
415 44. Tauzin A, *et al.* A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector  
416 functions and boost pre-existing humoral and T cell responses. *medRxiv [Preprint]*,  
417 2021.2003.2018.435972 (2021).
- 418  
419 45. Skowronski DM, *et al.* Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and  
420 extended dosing intervals: test-negative design studies from British Columbia and Quebec,  
421 Canada. *Clinical infectious diseases : an official publication of the Infectious Diseases Society  
422 of America*, ciac290 (2022).
- 423  
424 46. Miyamoto S, *et al.* Vaccination-infection interval determines cross-neutralization potency to  
425 SARS-CoV-2 Omicron after breakthrough infection by other variants.  
426 2021.2012.2028.21268481 (2022).
- 427  
428 47. Focosi D, Franchini M. Passive immunotherapies for COVID-19: The subtle line between  
429 standard and hyperimmune immunoglobulins is getting invisible. *Rev Med Virol*, e2341  
430 (2022).
- 431  
432 48. Klingler J, *et al.* Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *J Infect  
433 Dis* **223**, 957-970 (2020).
- 434  
435 49. Wang Z, *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Science translational  
436 medicine*, (2020).
- 437  
438 50. Awasthi M, Golding H, Khurana S. SARS-CoV-2 hyperimmune intravenous human  
439 immunoglobulins neutralizes Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.3 and BA.4/BA.5  
440 for treatment of COVID-19. *Clinical Infectious Diseases*, (2022).
- 441  
442 51. Wolter N, *et al.* Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant  
443 in South Africa. *Lancet* **399**, 437-446 (2022).
- 444

- 445 52. Iketani S, *et al.* Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages. *Nature*  
446 **604**, 553-556 (2022).
- 447  
448 53. Cao YR, *et al.* BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.  
449 *Nature*, (2022).
- 450  
451 54. Tuekprakhon A, *et al.* Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine  
452 and BA.1 serum. *Cell* **185**, 2422-2433.e2413 (2022).
- 453  
454 55. Tjan LH, *et al.* As well as Omicron BA.1, high neutralizing activity against Omicron BA.2 can  
455 be induced by COVID-19 mRNA booster vaccination. *J Infect Dis*, jiac159 (2022).
- 456  
457 56. Khan K, *et al.* Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing  
458 immunity. 2022.2004.2029.22274477 (2022).
- 459  
460 57. Willett BJ, *et al.* Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and  
461 BA.5. 2022.2005.2025.493397 (2022).
- 462  
463 58. Muik A, *et al.* Omicron BA.2 breakthrough infection enhances cross-neutralization of  
464 BA.2.12.1 and BA.4/BA.5. 2022.2008.2002.502461 (2022).
- 465  
466 59. Graham C, *et al.* The effect of Omicron breakthrough infection and extended BNT162b2  
467 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.  
468 2022.2008.2004.22278160 (2022).
- 469  
470 60. Yu J, *et al.* Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.  
471 2022.2002.2006.22270533 (2022).
- 472  
473 61. Seaman MS, *et al.* Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron  
474 (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses.  
475 2022.2003.2002.22271731 (2022).
- 476  
477 62. Zou J, *et al.* Cross neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2. *Nat*  
478 *Commun* **13**, 2956 (2022).
- 479  
480 63. Lapointe HR, *et al.* Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-  
481 dose COVID-19 vaccination. 2022.2005.2019.22275026 (2022).
- 482  
483 64. Hachmann NP, *et al.* Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1  
484 and BA.4/BA.5. *N Engl J Med* **387**, 86-88 (2022).

- 485  
486 65. Wang Q, *et al.* SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend  
487 antibody evasion. 2022.2005.2026.493517 (2022).
- 488  
489 66. Planas D, *et al.* Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2  
490 vaccinated individuals, with or without Omicron breakthrough infection.  
491 2022.2007.2022.22277885 (2022).
- 492  
493 67. Wang X, *et al.* Neutralization of Omicron BA.4/BA.5 and BA.2.75 by Booster Vaccination or  
494 BA.2 Breakthrough Infection Sera. 2022.2008.2004.502716 (2022).
- 495  
496 68. Zeng C, *et al.* Neutralization and Stability of SARS-CoV-2 Omicron Variant. *bioRxiv*, (2021).
- 497  
498 69. Liu L, *et al.* Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.  
499 *Nature* **602**, 676-681 (2022).
- 500  
501 70. Schmidt F, *et al.* Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N Engl J Med*  
502 **386**, 599-601 (2022).
- 503  
504 71. Arien KK, *et al.* Three doses of BNT162b2 vaccine confer neutralising antibody capacity  
505 against the SARS-CoV-2 Omicron variant. *NPJ Vaccines* **7**, 35 (2022).
- 506  
507 72. Lusvardi S, *et al.* SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum,  
508 but evades most convalescent serum and therapeutic antibodies. *Sci Transl Med*, eabn8543  
509 (2022).
- 510  
511 73. Hoffmann M, *et al.* The Omicron variant is highly resistant against antibody-mediated  
512 neutralization: Implications for control of the COVID-19 pandemic. *Cell* **185**, 447-456 e411  
513 (2022).
- 514  
515 74. Zou J, *et al.* Neutralization against Omicron SARS-CoV-2 from previous non-Omicron  
516 infection. *Nat Commun* **13**, 852 (2022).
- 517  
518 75. Zhang L, *et al.* The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.  
519 *Emerging microbes & infections* **11**, 1-5 (2022).
- 520  
521 76. Gruell H, *et al.* mRNA booster immunization elicits potent neutralizing serum activity against  
522 the SARS-CoV-2 Omicron variant. *Nat Med* **28**, 477-480 (2022).
- 523  
524 77. Dejnirattisai W, *et al.* SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from  
525 neutralizing antibody responses. *Cell* **185**, 467-484 e415 (2022).

- 526  
527 78. Sheward DJ, *et al.* Variable loss of antibody potency against SARS-CoV-2 B.1.1.529  
528 (Omicron). *bioRxiv*, 2021.2012.2019.473354 (2021).
- 529  
530 79. Tada T, *et al.* Increased resistance of SARS-CoV-2 Omicron variant to neutralization by  
531 vaccine-elicited and therapeutic antibodies. *EBioMedicine* **78**, 103944 (2022).
- 532  
533 80. Aggarwal A, *et al.* SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance  
534 to clinical immunotherapeutics relative to viral variants of concern. *medRxiv*,  
535 2021.2012.2014.21267772 (2021).
- 536  
537 81. Zhao X, *et al.* Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. *N*  
538 *Engl J Med* **386**, 894-896 (2022).
- 539  
540 82. Bowen JE, *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive  
541 panel of human vaccines. *bioRxiv*, (2022).
- 542  
543 83. Carreno JM, *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.  
544 *Nature* **602**, 682-688 (2022).
- 545  
546 84. Syed AM, *et al.* Omicron mutations enhance infectivity and reduce antibody neutralization of  
547 SARS-CoV-2 virus-like particles. *medRxiv*, (2022).
- 548  
549 85. Haveri A, *et al.* Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA  
550 vaccination in health care workers and elderly subjects. *Eur J Immunol*, (2022).
- 551  
552 86. Li M, *et al.* Convalescent plasma with a high level of virus-specific antibody effectively  
553 neutralizes SARS-CoV-2 variants of concern. *Blood advances*, 2022.2003.2001.22271662  
554 (2022).
- 555  
556 87. Kurahashi Y, *et al.* Cross-neutralizing activity against Omicron could be obtained in SARS-  
557 CoV-2 convalescent patients who received two doses of mRNA vaccination. *medRxiv*,  
558 2022.2002.2024.22271262 (2022).
- 559  
560 88. Lechmere T, *et al.* Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following  
561 Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. *mBio* **13**, e0379821  
562 (2022).
- 563  
564 89. Edara VV, *et al.* mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing  
565 activity against the SARS-CoV-2 omicron variant. *Cell Rep Med* **3**, 100529 (2022).


566

- 567 90. Cele S, *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.  
568 *Nature* **602**, 654-656 (2022).
- 569  
570 91. Wilhelm A, *et al.* Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera  
571 and Monoclonal Antibodies. *medRxiv*, 2021.2012.2007.21267432 (2021).
- 572  
573 92. Doria-Rose NA, *et al.* Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron  
574 Neutralization. *medRxiv*, 2021.2012.2015.21267805 (2021).
- 575  
576 93. Kawaoka Y, *et al.* Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.  
577 *Res Sq*, (2022).
- 578  
579 94. Dejnirattisai W, *et al.* Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by  
580 post-immunisation serum. *Lancet* **399**, 234-236 (2022).
- 581  
582  
583



584 **Figure 1**


585 PRISMA flowchart for the current study.



586  
587

588 **Figure 2**

589 Geometric mean neutralizing titers (GMT<sub>50</sub>) against WA-1 versus Omicron BA.1 by study for A)  
 590 unvaccinated convalescent plasma and B) vaccinated plasma with or without COVID-19. Geomeans for  
 591 entire study groups with neutralization of WA-1 in filled circles with Omicron in empty circles with  
 592 geomeans and fold reduction (FR) above data and number of studies above x-axis. All geomeans are not  
 593 statistically significant in difference by multiple comparison in Tukey's test.



594

595

596

597


598

599 **Figure 3**

600 Percent of individual plasma samples in each study showing any titer of Omicron BA.1 neutralization. The  
 601 percent of samples within a study condition which neutralized Omicron graphed in increasing  
 602 percentages with the number of samples tested on the right y axis. A) pre-Alpha CCP neutralization of  
 603 Omicron; B) Alpha, Beta and Delta CCP neutralization of Omicron C) 2 dose mRNA vaccines neutralization  
 604 of Omicron D) post-COVID-19/post-vaccine (VaxCCP) and uninfected 3-dose vaccine neutralization of  
 605 Omicron.

606

607



608

609


610

611

612

613 **Figure 4**

614 Geometric mean neutralizing titers (GMT<sub>50</sub>) of anti-WA.1 or anti-Omicron BA.1 neutralizing antibodies in  
 615 plasma samples from 5 studies investigating diverse SARS-CoV-2 infecting lineage or vaccination status. 5  
 616 studies characterized A) pre-Alpha, Alpha, Beta and Delta CCP for Omicron nAb compared to WA-1, and  
 617 also B) 2 or 3 doses BNT162b2 plasma, as well as post-COVID-19 plus BNT162b2 vaccine (VaxCCP). C) 9  
 618 additional studies looked at the same vaccine conditions in the first 5 comparing WA-1 nAb to Omicron  
 619 nAb.



620

621

622

623 **Table 1**

624 Comparison of WA-1 to Omicron BA.1 nAb and percent with any Omicron BA.1 nAb amongst VOC CCP  
 625 and vaccination status.

plasma type	number of studies	WA-1 nAb GMT <sub>50</sub>	Omicron BA1 nAb GMT <sub>50</sub>	fold reduction in nAb GMT <sub>50</sub> vs. Omicron BA.1	total number individuals in all studies	total Omicron BA.1 neutralizing number	Omicron BA.1 neutralizing percent
pre-Alpha	27	326	15	21	679	300	44
Alpha	6	227	5	45	101	38	38
Beta	5	91	8	11	37	19	51
Delta	7	462	42	11	94	69	73
2 dose BNT162b2 plasma	22	639	26	25	434	204	47
2 dose mRNA-1273 plasma	9	644	21	31	134	81	60
post-COVID-19/full vacc plasma	19	2977	211	14	305	269	88
3 dose BNT162b2 plasma	17	2,723	291	9	307	293	95

626

627 **Table 2**

628 Efficacy of CCP, vaccinee plasma and VaxCCP expressed as GMT<sub>50</sub> against Omicron sublineages. n.d. : no  
629 data.

CCP source	target Omicron sublineage					
	BA.1	BA.2	BA.2.12.1	BA.2.7.5	BA.4/5	BA.4.6/BA.4.7/BA.5.9
wild-type CCP (unvaccinated)	↓ <sup>52</sup> (including BA.1.1)	↓ <sup>52</sup>	n.d.	n.d.	n.d.	n.d.
uninfected 3-dose mRNA vaccinee plasma	↓ <sup>52</sup> (including BA.1.1) 15, 25	↓ <sup>52</sup>	n.d.	n.d.	stronger escape than BA.2 <sup>23, 53, 54</sup>	n.d.
any pre-Omicron VOC VaxCCP	n.d.	= <sup>55</sup>	n.d.	n.d.	<sup>24</sup>	n.d.
Delta VaxCCP	n.d.	n.d.	<sup>23</sup>	n.d.	<sup>23</sup>	n.d.
BA.1 CCP	↓ <sup>22</sup>	n.d.	n.d.	n.d.	7.5-7.6-fold lower than against BA.1 <sup>23, 53, 54, 56, 57</sup>	n.d.
BA.1 VaxCCP	1:2929 at 9-12 days <sup>15, 25, 50, 58, 59</sup>	1.3 to 1.8-fold lower <sup>52, 60, 61</sup> 4.2-fold lower <sup>62</sup> than against the parental BA.1 sublineage; no neutralization <sup>6</sup> <sub>3</sub> 50 59	1.8-fold lower than against BA.2 <sup>23, 53, 64, 65</sup> > 5-fold lower compared to wild-type <sup>58</sup> <sub>50</sub>	3-doses better than 2-doses <sup>28</sup>	2.6-3.2-fold lower than against BA.1 <sup>56, 57, 64, 66</sup> 4.5-fold lower than against BA.2 <sup>57</sup> > 5-fold lower compared to wild-type <sup>58</sup> <sub>50</sub> 59 3-doses slightly better than 2-doses <sup>28</sup>	1.5-1.9 fold lower than against BA.4/5 <sup>27</sup>
BA.2 CCP	no data	no data	no data	n.d.	poor <sup>57</sup> <sub>66</sub>	n.d.
BA.2 VaxCCP	1.2-fold lower compared to wild-type <sup>58</sup> <sub>59</sub> 67	1.5-fold lower compared to wild-type <sup>58</sup> <sub>59</sub> 67	2.5-fold lower compared to wild-type <sup>58</sup> <sub>67</sub>	n.d.	2.5-fold lower compared to wild-type <sup>58</sup> <sub>59</sub>	1.5-1.9 fold lower than against BA.4/5 <sup>27</sup>

					<sup>67</sup>	
BA.2.12.1 CCP	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
BA.2.12.1 VaxCCP	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
BA.4/5 CCP	557 (2-FR) <sup>24</sup>	884 (1-FR) <sup>24</sup>	n.d.	n.d.	1,047 <sup>24</sup>	n.d.
BA.4/5 VaxCCP	2,785 (2-FR) <sup>24</sup>	4244 (1-FR) <sup>24</sup>	n.d.	n.d.	3,779 <sup>24</sup>	2.4-2.6 fold lower than against BA.4/5 <sup>27</sup>

630

631



632 **Supplementary table 1**

633 Synopsis of *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron

634

reference	Time since infection	(pre-Alpha CCP) WA-1 GMT <sub>50</sub>	(pre-Alpha CCP) fold drop vs. BA.1	(pre-Alpha CCP) BA.1 GMT <sub>50</sub>	(pre-Alpha CCP) number in study	(pre-Alpha CCP) BA.1 neutralizing number	(pre-Alpha CCP) BA.1 neutralizing percent
Zeng <sup>68</sup>		4980	177	28	18	3	17
Liu <sup>69</sup>		4344	32	136	10	2	20
Schmidt <sup>70</sup>	1.2 mo	2616	38	69	20	19	95
Schmidt <sup>70</sup>	12 mo	2037	15	136	20	17	85
Schmidt <sup>70</sup>	6 mo	1678	49	34	20	13	65
Arien <sup>71</sup>		1086	22	49	10	1	10
Lusvarghi <sup>72</sup>		715	29	25	16	2	13
Hoffman <sup>73</sup>		614	80	8	17	8	47
Zou <sup>74</sup>		601	16	38	64	41	64
Planas <sup>14</sup>	6 mo	569	20	28	16	6	38
Planas <sup>14</sup>	12 mo	580	20	29	23	8	35
Zhang <sup>75</sup>		556	8	70	28	28	100
Gruell <sup>76</sup>	1.5 mo	494	82	6	30	3	10
Gruell <sup>76</sup>	12 mo	93	12	8	30	9	30
Dejnirattisai <sup>77</sup>		475	17	28	32	32	100
Sheward <sup>78</sup>		300	6	50	34	25	74
Tada <sup>79</sup>		233	26	9	10	4	40
Aggerwal <sup>80</sup>		210	21	10	20	0	0
Zhao <sup>81</sup>		193	17	11	16	1	6
Bowen <sup>82</sup>		162	16	10	28	13	46
Zou <sup>74</sup>		142	5	28	36	30	83
Carreno <sup>83</sup>		100	11	9	15	4	27
Syed <sup>84</sup>		80	4	20	8	6	75
Bekliz <sup>15</sup>		37	45	1	34	5	15
Haveri <sup>85</sup>		32	32	1	13	0	0
Li <sup>86</sup>		28	14	2	71	5	7
Kurahashi <sup>87</sup>		19	13	2	40	15	38
GM (GMT <sub>50</sub> )		326	21	15			44
total					679	300	

635

636 **Supplementary table 2**

637 Synopsis of *in vitro* studies investigating the efficacy of Alpha CCP against Omicron

reference	Time since infection	(Alpha CCP) WA-1 GMT <sub>50</sub>	(Alpha CCP) fold reduction vs. BA.1	(Alpha CCP) BA.1 GMT <sub>50</sub>	(Alpha CCP) number	(Alpha CCP) BA.1 neutralizing number	(Alpha CCP) BA.1 neutralizing percent
Lusvarghi <sup>72</sup>		4978	166	30	4	1	25
Dejnirattisai <sup>77</sup>		1313	34	39	18	18	100
Rosler <sup>16</sup>		260	64	4	10	0	0
Haveri <sup>85</sup>		64	32	2	20	0	0
Bekliz <sup>15</sup>		45	56	1	12	2	17
Li <sup>86</sup>		28	14	2	37	17	46
GM (GMT <sub>50</sub> )		525	65	8			38
total					101	38	

638

639

640 **Supplementary table 3**

641 Synopsis of *in vitro* studies investigating the efficacy of Beta CCP against Omicron.

reference	Time since infection	(beta CCP) WA-1 GMT <sub>50</sub>	(beta CCP) fold reduction vs. BA.1	(beta CCP) BA.1 GMT <sub>50</sub>	(beta CCP) number	(beta CCP) BA.1 neutralizing number	(beta CCP) BA.1 neutralizing percent
Lusvarghi <sup>72</sup>		439	2	220	2	2	100
Dejnirattisai <sup>77</sup>		327	12	28	14	14	100
Rosler <sup>16</sup>		128	32	4	8	1	13
Bekliz <sup>15</sup>		21	23	1	8	2	25
Haveri <sup>85</sup>		17	8	2	5	0	0
GM (GMT <sub>50</sub> )		140	11	13			51
Total					37	19	

642

643 **Supplementary table 4**

644 Synopsis of *in vitro* studies investigating the efficacy of Delta CCP against Omicron.

reference	Time since infection	(Delta CCP) WA-1 GMT <sub>50</sub>	(Delta CCP) fold drop vs. BA.1	(Delta CCP) BA.1 GMT <sub>50</sub>	(Delta CCP) number	(Delta CCP) BA.1 neutralizing number	(Delta CCP) BA.1 neutralizing percent
Zeng <sup>68</sup>		11200	3	3733	19	10	53
Lechmere <sup>88</sup>		4751	28	170	14	12	86
Lusvarghi <sup>72</sup>		1211	66	18	15	12	80
Aggerwal <sup>80</sup>		770	21	37	10	9	90
Rosler <sup>16</sup>		192	25	8	7	1	14
Bekliz <sup>15</sup>		72	24	3	10	6	60
Dejnirattisai <sup>77</sup>		47	2	27	19	19	100
GM (GMT <sub>50</sub> )		167	17	10			73
Total					94	69	

645

646 **Supplementary table 5**

647 Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 BNT162b2  
648 doses against Omicron.

reference	Time since second BNT162b2 dose	(2 dose BNT162b2 plasma) WA-1 GMT <sub>50</sub>	(2 dose BNT162b2 plasma) fold reduction vs. BA.1	(2 dose BNT162b2 plasma) BA.1 GMT <sub>50</sub>	(2 dose BNT162b2 plasma) number	(2 dose BNT162b2 plasma) BA.1 neutralizing number	(2 dose BNT162b2 plasma) BA.1 neutralizing percent
Schmidt <sup>70</sup>	1 mo	7627	83	92	18	15	83
Liu <sup>69</sup>		4669	21	222	13	6	46
Zeng <sup>68</sup>		2769	23	120	48	13	27
Schmidt <sup>70</sup>	5 mo	2435	19	128	18	15	83
Dejnirattisai <sup>77</sup>		1993	105	19	20	20	100
Chatterjee <sup>42</sup>		1544	2	935	25	25	100
Syed <sup>84</sup>		1280	16	80	21	14	67
Tada <sup>79</sup>		859	34	25	9	7	78
Bowen <sup>82</sup>		764	27	28	10	9	90
Chatterjee <sup>42</sup>		641	6	105	19	10	53
Hoffman <sup>73</sup>	3 mo	604	60	10	11	1	9
Lusvarghi <sup>72</sup>		562	26	22	39	3	8
Gruell <sup>76</sup>	1 mo	546	68	8	30	10	33
Rosler <sup>16</sup>	1 mo	512	32	16	20	9	45
Edara <sup>89</sup>	1 mo	384	19	20	13	2	15
Muik <sup>17</sup>		368	61	6	25	8	32
Cele <sup>90</sup>		359	19	19	8	7	88
Bekliz <sup>15</sup>		338	86	4	16	11	69
Planas <sup>14</sup>	5 mo	329	11	30	16	1	6
Carreno <sup>83</sup>		300	23	13	10	7	70
Gruell <sup>76</sup>	5 mo	139	15	9	30	11	37
Wilheim <sup>91</sup>		6	11	1	15	0	0
GM (GMT <sub>50</sub> )		639	25	26			47
Total					1319	35	

649

650 **Supplementary table 6**

651 Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 mRNA-  
 652 1273 doses against Omicron.

reference	time since second RNA-1273 dose	(2 dose mRNA-1273 plasma) WA-1 GMT <sub>50</sub>	(2 dose mRNA-1273 plasma) fold drop vs. BA.1	(2 dose mRNA-1273 plasma) BA.1 GMT <sub>50</sub>	(2 dose mRNA-1273 plasma) number	(2 dose mRNA-1273 plasma) BA.1 neutralizing number	(2 dose mRNA-1273 plasma) BA.1 neutralizing percent
Doria-Rose <sup>92</sup>		3016	48	63	30	22	73
Syed <sup>84</sup>		2560	8	320	10	8	80
Doria-Rose <sup>92</sup>		2269	84	27	30	22	73
Bowen <sup>82</sup>		1155	32	36	11	9	82
Tada <sup>79</sup>		999	26	38	8	5	63
Edara <sup>89</sup>	1 mo	745	50	15	11	4	36
Carreno <sup>83</sup>		400	43	9	10	10	100
Rosler <sup>16</sup>	5 mo	320	40	8	10	1	10
Wilheim <sup>91</sup>		10	20	1	14	0	0
GM (GMT <sub>50</sub> )		644	31	21			60
Total					134	81	

653

654 **Supplementary table 7**

655 Synopsis of *in vitro* studies investigating the efficacy of plasma from infected and vaccinated (2 BNT162b2  
656 doses) subjects (VaxCCP) against Omicron.

reference	month since last event (either infection or vaccination)	(post-COVID-19/full vacc plasma) WA-1 GMT <sub>50</sub>	(post-COVID-19/full vacc plasma) fold drop vs. BA.1	(post-COVID-19/full vacc plasma) BA.1 GMT <sub>50</sub>	(post-COVID-19/full vacc plasma) number	(post-COVID-19/full vacc plasma) BA.1 neutralizing number	(post-COVID-19/full vacc plasma) BA.1 neutralizing percent
Schmidt <sup>70</sup>		388872	48	8102	17	17	100
Planas <sup>14</sup>		78162	53	1475	22	22	100
Tada <sup>79</sup>		14868	16	929	7	7	100
Cele <sup>90</sup>		13333	25	533	13	13	100
Kawoaka <sup>93</sup>		10863	16	665	5	5	100
Kawoaka <sup>93</sup>		10002	7	1369	13	13	100
Lechmere <sup>88</sup>		8843	5	1769	15	15	100
Gruell <sup>76</sup>		7997	5	1599	30	30	100
Arien <sup>71</sup>		4822	20	241	10	10	100
Carreno <sup>83</sup>		3000	14	214	10	10	100
Dejnirattisai <sup>77</sup>		1899	9	215	17	17	100
Li <sup>86</sup>		1598	20	80	20	20	100
Bekliz <sup>15</sup>		1190	18	66	6	6	100
Haveri <sup>85</sup>		1024	32	32	33	33	100
Rosler <sup>16</sup>		1000	4	250	5	5	100
Edara <sup>89</sup>		625	20	31	24	15	63
Kurahashi <sup>87</sup>	12 mo	369	7	51	19	19	100
Wilheim <sup>91</sup>		200	32	6	20	5	25
Kurahashi <sup>87</sup>	1 mo	22	14	2	19	7	37
GM (GMT <sub>50</sub> )		3124	15	210			88
total					305	269	

657

658 **Supplementary table 8**

659 Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with  
 660 3 BNT162b2 doses against Omicron.

reference	Time since third BNT162b2 vaccine dose	(3 dose BNT162b2 plasma) WA-1 GMT <sub>50</sub>	(3 dose BNT162b2 plasma) fold drop vs. BA.1	(3 dose BNT162b2 plasma) BA.1 GMT <sub>50</sub>	(3 dose BNT162b2 plasma) number	(3 dose BNT162b2 plasma) BA.1 neutralizing number	(3 dose BNT162b2 plasma) BA.1 neutralizing percent
Schmidt <sup>70</sup>	1 mo	65617	17	3860	18	18	100
Planas <sup>14</sup>		12739	18	708	20	20	100
Zeng <sup>68</sup>		10412	3	3155	23	20	87
Dejnirattisai <sup>77</sup>		9219	14	649	20	20	100
Gruell <sup>76</sup>	1 mo	6241	5	1248	30	30	100
Lusvarghi <sup>72</sup>		5029	7	718	39	39	100
Tada <sup>79</sup>		4892	14	349	12	12	100
Liu <sup>69</sup>		4673	7	668	15	15	100
Kawoaka <sup>93</sup>		2866	6	485	10	10	100
Arien <sup>71</sup>		2157	13	166	10	10	100
Hoffman <sup>73</sup>	1 mo	2006	7	287	10	9	90
Edara <sup>89</sup>		1247	14	89	35	31	89
Carreno <sup>83</sup>		1000	8	125	10	10	100
Syed <sup>84</sup>		960	4	240	8	8	100
Muik <sup>17</sup>		673	6	112	28	27	96
Haveri <sup>85</sup>		290	12	24	7	7	100
Wilheim <sup>91</sup>	0.5 mo	150	37	4	12	7	58
GM (GMT <sub>50</sub> )		2723	9	291			95
total					307	293	

661

662



663 **Supplementary table 9**

664 Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with  
 665 3 doses of mRNA-1273, AZD-1222 or Ad26.CO2 against BA.1. Because of diversity of vaccines the  
 666 geomeans and sums were not computed.

667

reference	vaccine type	WA-1 GMT <sub>50</sub>	fold drop vs. BA.1	BA.1 GMT <sub>50</sub>	number	BA.1 neutralizing number	BA.1 neutralizing percent
Careno <sup>83</sup>	COVID19 + mRNA-1273	3000	11	272	10	10	100
Edara <sup>89</sup>	COVID19 + mRNA-1273 6 mo	931	25	38	13	9	69
Careno <sup>83</sup>	3 dose mRNA-1273	1000	17	60	10	10	100
Doria-Rose <sup>92</sup>	3 dose mRNA-1273	8457	4	2002	30	30	100
Doria-Rose <sup>92</sup>	3 dose mRNA-1273	4216	6	650	30	30	100
Edara <sup>89</sup>	3 dose mRNA-1273	1395	15	96	17	16	94
Dejnirattisai <sup>94</sup>	AZD1222	390	19	21	41	41	100
Rosler <sup>16</sup>	AZD1222	250	25	10.0	20	0	0
Planas <sup>14</sup>	AZD1222 5 mo	187	18	10	18	2	10
Syed <sup>84</sup>	Ad26.CO2	28	1	20.0	9	2	22
Schmidt <sup>70</sup>	Ad26.CO2 1 mo	588	24	25	19	2	11
Schmidt <sup>70</sup>	Ad26.CO2 6 mo	982	23	43	19	11	58

668

